448954-09-4Relevant articles and documents
Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators
Link,Sorensen, Bryan,Patel, Jyoti,Grynfarb, Marlena,Goos-Nilsson, Annika,Wang, Jiahong,Fung, Steven,Wilcox, Denise,Zinker, Brad,Nguyen, Phong,Hickman, Bach,Schmidt, James M.,Swanson, Sue,Tian, Zhenping,Reisch, Thomas J.,Rotert, Gary,Du, Jia,Lane, Benjamin,Von Geldern, Thomas W.,Jacobson, Peer B.
, p. 5295 - 5304 (2007/10/03)
Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2- alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA 1c, triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.
GLUCOCORTICOID RECEPTOR MODULATORS
-
, (2008/06/13)
Compounds of formula (I) or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.
